All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 CD22 (HA22SH) h(28OXζ), which is constructed for the engineering of T cells to target human CD22. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-CD22 antibody linked to a CD28 transmembrane domain/ endodomain and OX40, CD3-zeta signaling domains. And the vector product was designed for the treatment of Acute lymphoblastic leukemia (ALL).
CAR Construction : HA22SH-CD28-CD3ζ Fig.1 Comparison of CD22-CAR and CD19-CAR-mediated lysis. 51Cr-release assay to evaluate lytic activity of CD22 HA22SH-28z second-generation CAR (inverted triangle), m971-28z second-generation CAR (gray triangle), CD19 CAR (squares), or mock transduced T cells (circles) against ALL lines. Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology, 121(7), 1165-1174. |
CAR Construction : HA22SH-CD28-CD3ζ, HA22SH-CD28-41BB-CD3ζ Fig.2 Cytokine release by CAR-transduced T cells. CAR-transduced T cells (vectors listed, x-axis) were incubated with irradiated CD22-high (Raji, column 1), CD22-low (NALM6-GL, column 2), or CD22-negative (K562, column 3) leukemia cell lines at a ratio of 10:1 for 24 hours and culture supernatants analyzed for IFN-γ (top row), IL-2 (second row), and TNF-α (third row). Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology, 121(7), 1165-1174. |
CAR Construction : HA22SH-CD28-CD3ζ Fig.3 Evaluation of CD22 CARs in vivo. On day 0, NSG mice were injected intravenously with 5 × 10^5 NALM6-GL cells. On day 3 mice received 1 × 10^7 CAR+ T cells (HA22SH-28z (n = 5) or m971-28z (n = 5) or mock T cells (n = 5). Bioluminescent imaging pre-treatment (day 3), day 7 and day 15 after intravenous injection of NALM6-GL. Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., ... & Orentas, R. J. (2013). Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, The Journal of the American Society of Hematology, 121(7), 1165-1174. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD22 (HA22SH) h(CD28-OX40-CD3ζ) CAR, pSBCAR1 (CAR-SB-02LX253). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION